Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.

Autor:	Marín F; Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, CIBERCV, Murcia, Spain., Fernández MS; Department of Cardiology, Hospital Universitario Ramon y Cajal, Madrid, Spain., Barón-Esquivias G; Department of Cardiology, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, Sevilla, Spain.; Unidad Cardiovascular, Instituto de Biotecnología de Sevilla. Centro de Investigación en Red Cardiovascular, Madrid, Spain., Barrios V; Department of Cardiology, University Hospital Ramón y Cajal, Alcalá University, Madrid, Spain., Lekuona I; Hospital Galdakao-Usansolo, Bizkaia, Spain., Pérez-Cabeza AI; Department of Cardiology, Virgen de la Victoria University Hospital, Málaga, Spain., Masjuan J; Servicio de Neurología, Hospital Universitario Ramón y Cajal, IRYCIS, Departamento de Medicina, Universidad de Alcalá. Red INVICTUS, Madrid, Spain., Del Vigo ER; Hospital Universitario de Basurto, Centro Médico San Juan de Dios, Bizkaia, Spain., Vázquez Rodríguez JM; Department of Cardiology, Complejo Hospitalario Universitario A Coruña, INIBIC, CIBERCV, A Coruña, Spain., Freixa-Pamias R; Department of Cardiology, Hospital Moisés Broggi, Barcelona, Spain., Schilling VR; Department of Haematology & Clinical Oncology, Hospital Universitario Morales Meseguer. University of Murcia, Murcia, Spain., Arribas F; Department of Cardiology, Hospital Universitario 12 de Octubre, Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.; Instituto de Investigacion Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain., Priu CR; Department of Medical Affairs, Bayer Hispania, Barcelona, Spain., Sánchez MA; Department of Cardiology, Hospital Reina Sofía Córdoba, IMIBIC, University of Cordoba, Córdoba, Spain.
Jazyk:	angličtina
Zdroj:	Journal of comparative effectiveness research [J Comp Eff Res] 2023 Mar; Vol. 12 (3), pp. e220049. Date of Electronic Publication: 2023 Feb 07.
DOI:	10.57264/cer-2022-0049
Abstrakt:	Aim: It is not well known how comorbidities may change the prognosis of atrial fibrillation (AF) patients. This study was aimed to analyze the impact of cardiovascular disease on this population. Materials & methods: EMIR was a multicenter, prospective study, including 1433 AF patients taking rivaroxaban for ≥6 months. Data were analyzed according to the presence of vascular disease. Results: Coronary artery disease was detected in 16.4%, peripheral artery disease/aortic plaque in 6.7%, vascular disease in 28.3%. Patients with coronary artery disease had higher rates (per 100 patient-years) of major adverse cardiovascular events (2.98 vs 0.71; p < 0.001) and cardiovascular death (1.79 vs 0.41; p = 0.004). Those with vascular disease had higher rates of thromboembolic events (1.47 vs 0.44; p = 0.007), major adverse cardiovascular events (2.03 vs 0.70; p = 0.004), and cardiovascular death (1.24 vs 0.39; p = 0.025). Patients with peripheral artery disease/aortic plaque had similar rates. Conclusion: AF patients with vascular disease have a higher risk of non-embolic outcomes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu